ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
TTUHSC Researchers Find Blood-Brain Barrier Remains Resilient in Alzheimer’s Disease Model
A team of scientists at TTUHSC has published new evidence suggesting that the brain’s protective shield remains largely intact in a commonly used mouse model of Alzheimer’s disease.
Collaborative Team Earns Five-Year Renewal Grant from NINDS to Continue Stroke Research
Due to this high level of productivity and potential to create new medications for stroke injury, NINDS recently awarded a new $3 million competitive renewal that extends the grant for an additional five years.
TTUHSC School of Medicine Resident Making an Impact as Published Researcher
During the current fiscal year, Pojsakorn Danpanichkul, M.D., has contributed to 19 papers in high-impact journals, including nine on which he served as first author.
Recent Stories
TTUHSC Researchers Find Blood-Brain Barrier Remains Resilient in Alzheimer’s Disease Model
A team of scientists at TTUHSC has published new evidence suggesting that the brain’s protective shield remains largely intact in a commonly used mouse model of Alzheimer’s disease.
Texas Tech University Health Sciences Center School of Nursing Named Best Accelerated Bachelor of Science in Nursing Program in Texas
The TTUHSC School of Nursing Accelerated Bachelor of Science in Nursing (BSN) program has been ranked the No. 1 accelerated nursing program in Texas by RegisteredNursing.org.
TTUHSC School of Nursing Hosts Renowned Nursing Theorist
Internationally recognized nursing leader Jean Watson, Ph.D., RN, presented, “Overview of Caring Science,” on Friday, Sept.12 at the Texas Tech University Health Sciences Center.